Evaluation of the effectiveness and safety of anti-obesity drugs - an update on the current state of knowledge on available and investigational drugs
DOI:
https://doi.org/10.12775/JEHS.2023.35.01.008Keywords
Obesity, anti-obesity drugs, GLP-1 analogs, liraglutide, phentermine/topiramate, naltrexone/bupropion, lorcaserin, orlistatAbstract
Introduction and purpose of the work: Disturbing epidemiological data indicate that obesity has become a global problem and has reached the size of a worldwide epidemic. The search for effective methods of combating obesity seems to be an important step in preventing cardiovascular diseases and numerous metabolic complications. The aim of the study is to assess the effectiveness and safety of available drugs used in the treatment of obesity in accordance with the current state of knowledge and to present new pharmacological options.
State of knowledge: Pharmacotherapy provides overweight and obese adults with the opportunity to support weight reduction in the event of failure of lifestyle modifications. Currently registered drugs for the treatment of obesity are orlistat, lorcaserin, liraglutide and combination preparations: phentermine/topiramate and naltrexone SR/bupropion SR.
Summary: Among the currently available drugs for obesity, the most effective are phentermine/topiramate and liraglutide. Research is also underway on the use of new substances that promote weight loss. The latest data on semaglutide and tirzepatide have better efficacy results compared to currently available drugs with a similar safety profile. The latest data on semaglutide and tirzepatide improve the efficacy results of current drugs while maintaining a similar safety profile. It seems that the best way to lose excessive body weight should be an individualized approach to the treatment of obesity among patients, taking into account i.a. degree of obesity, comorbidities, contraindications, patient preferences, cost and availability of treatment. In clinical practice, when choosing a drug, we should pay attention to side effects and find a balance between effectiveness and safety. In addition to weight loss, the use of anti-obesity drugs has many additional benefits, including improvement of the cardiometabolic profile, reduction of glucose, insulin and lipids in the blood.
References
World Health Organization: Obesity: Preventing and Managing the Global Epidemic (WHO Technical Report Series). World Health Organisation. ISBN 92-4-120894-5.
World Health Organization: Obesity and overweight. 09/06/2021.
Conway B, Rene A. Obesity as a disease: no lightweight matter. Obes Rev. 2004 Aug;5(3):145-51. doi: 10.1111/j.1467-789X.2004.00144.x. PMID: 15245383.
Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 2014;63:2895–3023. ** Guidelines for pharmacotherapy in obesity.
Guidance for Industry Developing Products for Weight Management. https://www.fda.gov/media/71252/download (Accessed April, 2023)
Tak YJ, Lee SY. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Curr Obes Rep. 2021 Mar;10(1):14-30. doi: 10.1007/s13679-020-00422-w. Epub 2021 Jan 6. PMID: 33410104; PMCID: PMC7787121
Henness S, Perry CM. Orlistat: a review of its use in the management of obesity. Drugs. 2006;66(12):1625-56. doi: 10.2165/00003495-200666120-00012. PMID: 16956313.
Orlistat (Xenical) US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020766s026lbl.pdf (Last accessed, April 15, 2023)
Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol. 2020 Jan;13(1):53-64. doi: 10.1080/17512433.2020.1698291. Epub 2019 Dec 22. PMID: 31770497
Hurt RT, Mundi MS, Ebbert JO. Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release. Diabetes Metab Syndr Obes. 2018 Sep 4;11:469-478. doi: 10.2147/DMSO.S126855. PMID: 30233224; PMCID: PMC6130259.
Lorcaserin (Belviq) US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022529lbl.pdf (Last accessed, April 15, 2023)
Sharretts J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. NEJM cancer risk associated with lorcaserin — the FDA’s review of the CAMELLIA-TIMI 61 Trial. N Engl J Med. 2020;383(11):1000–1002.
The US Food and Drug Administration, 01-14-2020 FDA Drug Safety Communication [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2020. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/safety-clinical-trial-shows-possible-increased-risk-cancer-weight-loss-medicine-belviq-belviq-xr. Accessed 16 Oct 2020
The US Food and Drug Administration, 02-13-2020 FDA Drug Safety Communication [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; c2020 Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market Accessed 16 Oct 2020.
Shanahan WR, Rose JE, Glicklich A, Stubbe S, Sanchez-Kam M. Lorcaserin for smoking cessation and associated weight gain: a randomized 12-week clinical trial. Nicotine Tob Res. 2017;19(8):944–951.
Haddock CK, Poston WSC, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002; 26(2): 262–273, doi: 10.1038/ sj.ijo.0801889, indexed in Pubmed: 11850760.
Smith SM, Meyer M, Trinkley KE. Phentermine/topiramate for the treatment of obesity. Ann Pharmacother. 2013 Mar;47(3):340-9. doi: 10.1345/aph.1R501. PMID: 23482732.
Lei XG, Ruan JQ, Lai C, Sun Z, Yang X. Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis. Obesity (Silver Spring). 2021 Jun;29(6):985-994. doi: 10.1002/oby.23152. Epub 2021 Apr 16. PMID: 33864346.
Phentermine/topiramate (Qsymia) US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022580s000lbl.pdf (Last accessed, April 15, 2023)
Naltrexone/bupropion for obesity. Drug Ther Bull. 2017 Nov;55(11):126-129. doi: 10.1136/dtb.2017.11.0550. PMID: 29117992.
Barrea L, Pugliese G, Muscogiuri G, Laudisio D, Colao A, Savastano S. New- generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. Minerva Endocrinol. 2020 Jun;45(2):127-137. doi: 10.23736/S0391-1977.20.03179-X. PMID: 32643356.
Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014; 84: 1–11, doi: 10.1016/j.phrs.2014.04.004, indexed in Pubmed: 24754973
Naltrexone/bupropion (Contrave) US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf (Last accessed, April 15, 2023)
European Medicines Agency, 2015. Mysimba (naltrexone/bupropion). Available: http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Public_assessment_report/human/003687/WC500185582.pdf [Accessed 18 October 2017].
Zhang P, Liu Y, Ren Y, Bai J, Zhang G, Cui Y. The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis. Afr Health Sci. 2019 Sep;19(3):2591-2599. doi: 10.4314/ahs.v19i3.35. PMID: 32127832; PMCID: PMC7040262.
Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab. 2009;11(Suppl 3):26–34. [PubMed] [Google Scholar]
van Can J, Sloth B, Jensen CB, et al. Effects of the oncedaily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, nondiabetic adults. Int J Obes (Lond) 2014;38:784–793. [PMC free article] [PubMed] [Google Scholar]
Flint A, Raben A, Ersboll AK, et al. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes. 2001;25:781–792. [PubMed] [Google Scholar]
Larsen PJ, Fledelius C, Knudsen LB, et al. Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes. 2001;50:2530–2539. [PubMed] [Google Scholar]
Guo X, Zhou Z, Lyu X, Xu H, Zhu H, Pan H, Wang L, Yang H, Gong F. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis. Horm Metab Res. 2022 Jul;54(7):458-471. doi: 10.1055/a-1844-1176. Epub 2022 May 5. PMID: 35512849
Christou GA, Katsiki N, Blundell J. et al. Semaglutide as a promising antiobesity drug. Obes Rev 2019; 20: 805-815
Iqbal J, Wu HX, Hu N, Zhou YH, Li L, Xiao F, Wang T, Jiang HL, Xu SN, Huang BL, Zhou HD. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta- analysis of randomized control trials. Obes Rev. 2022 Jun;23(6):e13435. doi: 10.1111/obr.13435. Epub 2022 Feb 22. PMID: 35194917.
Xia L, Shen T, Dong W, Su F, Wang J, Wang Q, Niu S, Fang Y. Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis. Diabetes Res Clin Pract. 2021 Jul;177:108904. doi: 10.1016/j.diabres.2021.108904. Epub 2021 Jun 6. PMID: 34102249.
Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials. Obes Rev. 2023 Mar;24(3):e13543. doi: 10.1111/obr.13543. Epub 2022 Dec 29. PMID: 36579723.
Ryan PM, Seltzer S, Hayward NE, Rodriguez DA, Sless RT, Hawkes CP. Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: A Meta-Analysis. J Pediatr. 2021 Sep;236:137-147.e13. doi: 10.1016/j.jpeds.2021.05.009. Epub 2021 May 11. PMID: 33984333.
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001/jama.2016.7602. Erratum in: JAMA. 2016 Sep 6;316(9):995. PMID: 27299618; PMCID: PMC5617638.
Smith SR, Garvey WT, Greenway FL, et al. Coadministration of lorcaserin and phentermine for weight management: a 12-week, randomized, pilot safety study. Obesity 2017;25:857– 65
Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014 Jan 1;311(1):74-86. doi: 10.1001/jama.2013.281361. PMID: 24231879; PMCID: PMC3928674.
Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, Chen Z, Xu S, Shen Y, Ge L, Sun F, Li L, Yu J, Nong K, Zou X, Zhu S, Wang C, Zhang S, Qiao Z, Jian Z, Li Y, Zhang X, Chen K, Qu F, Wu Y, He Y, Tian H, Li S. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022 Jan 15;399(10321):259-269. doi: 10.1016/S0140-6736(21)01640-8. Epub 2021 Dec 8. PMID: 34895470.
Camilleri M, Acosta A. Gastrointestinal traits: individualizing therapy for obesity with drugs and devices. Gastrointest Endosc. 2016; 83(1):48–56. [PubMed: 26271184]
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Katarzyna Cichoń, Małgorzata Chyćko, Julia Czarnota, Agata Kromer, Magdalena Alicja Zapała, Agnieszka Środoń, Joanna Wilk, Małgorzata Maria Cholewa, Agnieszka Gawryś, Monika Łapaj
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 471
Number of citations: 0
